Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telaprevir Duration Study in HCV Genotype 1 IL28B CC Patients
NCT01459913Phase 3Terminated
- Sponsor
- Vertex Pharmaceuticals
- Start
- Nov 2011
- Primary completion
- Jan 2014
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, open-label trial of telaprevir in hepatitis C (HCV) (4 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Sustained Viral Response 12 Weeks After Last Planned Dose. Started Nov 2011; status: terminated.
02
Drugs
telaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01459913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01459913.